Breakthrough PTSD treatment achieves 68% remission rate in clinical trial
A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the way for more precise treatments for other mental health conditions.
We haven't written up this one. ScienceDaily has the full story — the link below goes straight to it.
